afatinib + carboplatin

Afatinib + carboplatin is an investigational **combination therapy** for advanced solid tumors, especially studied in non-small cell lung cancer (NSCLC). **Afatinib** is an irreversible ErbB family blocker (targeting epidermal growth factor receptor EGFR, human epidermal growth factor receptor 2 HER2, and ErbB4), administered orally, while **carboplatin** is a platinum-based chemotherapeutic agent that induces DNA damage to inhibit tumor growth, administered intravenously. The rationale for combining these agents is based on their non-overlapping mechanisms of action: afatinib provides targeted inhibition of oncogenic signaling via ErbB family kinases, while carboplatin induces cytotoxicity through DNA crosslinking. This combination has been evaluated in phase I trials, notable for demonstrating **manageable safety** and preliminary **antitumor activity**, with recommended phase II dosing of afatinib 40 mg/day plus carboplatin AUC6[1][2]. Most frequent drug-related adverse events include rash, fatigue, and diarrhea[1][2].